On This Page
Applications | Protocols | FAQ | Contact an Expert
Transform Your Cell Therapy Manufacturing With Non-Viral Gene Delivery
Fast, Scalable, and Cost-Effective Stable Gene Transfer Solution
TcBuster is a large capacity transposon system that enables transfer and stable integration of multiple genes of interest. An effective alternative to viral vectors, TcBuster offers significant time and cost savings during the development of cell therapies, such as CAR T or CAR NK.
TcBuster Reagents and Uses | |||
mRNA Transposase | TCB-001.1-100 (100 µg) | 100 tests at 1 µg each | - Useful for system evaluation |
| TCB-001.1-500 (500 µg) | 500 tests at 1 µg each | - Useful for further development | |
| TCB-001.1-GMP (500 µg) | 500 tests at 1 µg each | - GMP grade - Useful for pre-IND process development and clinical applications | |
TcBuster-Compatible Transposons | TCBP001-100 (100 µg) | 25-100 tests at 1-4 µg each | - Multicistronic CAR-containing transposon - Useful in cell therapy applications |
| TCBP002-100 (100 µg) | 25-100 tests at 1-4 µg each | - Whole plasmid insertion with GFP and no plasmid expression - Useful in bioprocessing system evaluation and cell therapy applications | |
| Custom Transposons | Contact techsupport@bio-techne.com for information | - For process development using your own therapeutic cargo - Utilizes partnership with Aldevron™ | |
Anti-TcBuster-M Transposase Antibody | MAB11511 (25 µg, 100 µg) | 1 µg/mL for Western Blot 20 µg/mL for Simple Western | - Primary antibody detects TcBuster-M transposase enzyme in Western blotting applications |
How Does the TcBuster System Compare to Virus-Based Systems?
Gene transfer is a critical step in generating cell therapies and biologics. While viral vector-based engineering (e.g. lentivirus or AAV) has been the standard for delivering DNA cargo to cells, the TcBuster system provides an alternative, non-viral solution using standard electroporation methods. This system has several advantages over traditional viral options:
Reduced time to market and cost requirements for cell therapies
Increased cargo capacity, high editing efficiency, and delivery of multiple genes in single vector
Stable expression of DNA cargo with a de-risked insertional profile
Strong and reliable supply chain for both RUO & GMP grade material
Scale effortlessly from research to clinical and commercial stages with reduced batch-to-batch variability and no need for viral preps
Flexible and non-exclusive license options plus robust technical and regulatory support
Saving Time Means Saving Money: Get Your Therapy to Market Faster
A Story of Success: Luminary Therapeutics
Luminary Therapeutics is using the TcBuster system to manufacture their cell therapies, and their LMY-920 program has passed 3 INDs with TcBuster! At SITC 2024, Phase 1 results were reported for a BAFF CAR-T trial using TcBuster, demonstrating the first successful clinical use of the system.
"Moreover, the novel, clinical-stage TcBuster transposon system is utilized to improve manufacturing timelines, efficiency, cost, and safety."
TcBuster for Bioprocessing:
Compared to Random Integration
This platform is flexible! By adjusting TcBuster system parameters, you can achieve high copy number of your sequences in your CHO or HEK cells. The integrated cargo is high-expressing and stable over extended culture times.
How Can Bio-Techne Support You and Your Projects?
We are your partner in cell therapy - and we have solutions to your cell therapy roadblocks.
Bio-Techne is here to stay, with over 40 years of scientific excellence
We provide a strong supply chain, for both our research grade and GMP products
We offer flexible licensing on our materials when you bring them the clinic or commercialization
Regulatory support, with a DMF coming soon, and the ability to support worldwide customers with letters of authorization
Robust technical service to support you while you evaluate the system
| TcBuster Resources | Scientific Articles and Presentations | ||
| Literature | Videos & Webinars | Papers | Posters & Abstracts |
| TcBuster-M + Nanoplasmid Vector System | Non-Viral Gene Delivery with TcBuster | Bridge et al. | Caimi et al. BAFF CAR-T Study |
| Non-Viral Gene Engineering Whitepaper | Transposon Gene Editing Mechanism | Gurney et al. | TcBuster vs. Lentivirus in T Cells |
| TcBuster v. Lentivirus App Note | Cell Therapy Development Webinar | Gurney et al. (2) | TcBuster-M System in T Cells |
| CAR-T Manufacturing Webinar | Skeate et al. | ||
| Wong et al. | |||
Partner with ScaleReady for TcBuster applications in immune cell therapy.
For other applications using TcBuster, contact a gene engineering expert at Bio-Techne.